Infectious complications and mortality associated with the use of IV iron therapy: a systematic review and meta-analysis

International Urology and Nephrology

Volumn 51, Issue 10, 2019, Pages 1855-1865

  Salim, Sohail Abdul ^a   Cheungpasitporn, Wisit ^a   Elmaraezy, Ahmad ^b   Jawafi, Omar ^c   Rahman, Md ^c   Aeddula, Narothama Reddy ^d   Tirupathi, Raghavendra ^e   Fülöp, Tibor ^f,g  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Al Razi Medical Research Academy   (Egypt)

^c Jackson State University   (United States)

^d Deaconess Health System   (United States)

^e Department of Internal Medicine   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Anemia; ESRD; Infections; Meta analysis; Mortality

Indexed keywords

DEXTRIFERRON; FERRIC CHLORIDE; FERRIC GLUCONATE; FERRIC HYDROXIDE; FERROUS FUMARATE; FERROUS SULFATE; FERUMOXYTOL; IRON; IRON DEXTRAN; IRON SACCHARATE;

ALL CAUSE MORTALITY; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; END STAGE RENAL DISEASE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK; LOW DRUG DOSE; META ANALYSIS; MORTALITY; MORTALITY RISK; RISK FACTOR; SYSTEMATIC REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION; EPIDEMIOLOGY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRAVENOUS; ANEMIA; HOSPITALIZATION; HUMANS; INCIDENCE; INFECTIONS; IRON; KIDNEY FAILURE, CHRONIC; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85072163964     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-019-02273-4     Document Type: Article

References (47)

1. Jha V, Modi GK (2018) Getting to know the enemy better—the global burden of chronic kidney disease. Kidney Int 94(3):462–464
2. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F et al (2004) Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 44(1):94–111
3. Wish JB (2006) Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1(Supplement 1):S4–S8
4. Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23(10):1631–1634
5. Hörl WH (2002) Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transpl 17(suppl_11):35–38
6. Moore LL, Humbert JR (1984) Neutrophil bactericidal dysfunction towards oxidant radical-sensitive microorganisms during experimental iron deficiency. Pediatr Res 18(8):789–794
7. Macdougall IC, Bircher AJ, Eckardt K-U, Obrador GT, Pollock CA, Stenvinkel P et al (2016) Iron management in chronic kidney disease: conclusions from a “kidney disease: improving global outcomes”(KDIGO) controversies conference. Kidney Int 89(1):28–39
8. Shepshelovich D, Rozen-Zvi B, Avni T, Gafter U, Gafter-Gvili A (2016) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis 68(5):677–690
9. Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P et al (2018) Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 13(3):457–467
10. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA et al (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458
11. Higgins JP, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. Wiley
12. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269
13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
14. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605
15. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB, Group USISCT (2006) Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):475–482
16. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ (2009) Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 4(2):386–393
17. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJ, Murray H, Tomson CR, Wheeler DC, Winearls CG (2019) Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5):447–458
18. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L (1998) Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 79(3):299–305
19. Fishbane S, Frei GL, Maesaka J (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26(1):41–46
20. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV et al (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to iv Iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 18(3):975–984
21. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S et al (2000) Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11(3):530–538
22. Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL et al (2014) Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transpl 30(4):667–675
23. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B et al (2015) Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int 87(1):162–168
24. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ (2014) Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol 9(11):1930–1939
25. Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA (2014) Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. BMC Nephrol 15(1):154
26. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA (2013) Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 8(11):e78930
27. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV (2013) Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24(7):1151–1158
28. Kuo K-L, Hung S-C, Lin Y-P, Tang C-F, Lee T-S, Lin C-P et al (2012) Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One 7(12):e50295
29. Pollak VE, Lorch JA, Shukla R, Satwah S (2009) The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 10(1):6
30. Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R et al (2008) Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19(2):372–379
31. Kopelman RC, Smith L, Peoples L, Biesecker R, Rizkala AR (2007) Functional iron deficiency in hemodialysis patients with high ferritin. Hemodial Int 11(2):238–246
32. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16(10):3070–3080
33. Varas J, Ramos R, Aljama P, Pérez-García R, Moreso F, Pinedo M et al (2017) Relationships between iron dose, hospitalizations and mortality in incident haemodialysis patients: a propensity-score matched approach. Nephrol Dial Transpl 33(1):160–170
34. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W et al (2004) Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15(6):1623–1632
35. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M et al (2002) Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 13(3):734–744
36. Hoen B, Paul-Dauphin A, Kessler M (2002) Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 57(6):457–461
37. Canziani MEF, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA (2001) Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment. Artif Organs 25(11):866–869
38. Fülöp T, Tapolyai MB, Agarwal M, Lopez-Ruiz A, Molnar MZ, Dossabhoy NR (2017) Bedside tunneled dialysis catheter removal—a lesson learned from nephrology trainees. Artif Organs 41(9):810–817
39. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT et al (2015) Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26(2):493–503
40. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J et al (2015) Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol 26(10):2578–2587
41. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A (2015) The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90(1):12–23
42. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U (2008) Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 52(5):897–906
43. Susantitaphong P, Alqahtani F, Jaber BL (2014) Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 39(2):130–141
44. Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F et al (2017) Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the dialysis outcomes and practice patterns study (DOPPS). BMC Nephrol 18(1):330
45. Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A (2015) Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88(5):1187–1194
46. Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD et al (2015) Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transpl 30(12):2019–2026
47. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A (2014) Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 86(4):845–854